The clinical pharmacogenetics of antipsychotic drugs
Pharmacogenetic testing in psychiatry has been rapidly developing over the recent decade. The review investigates genetic polymorphisms most intensely studied to date that determine the pharmacokinetic and pharmacodynamic parameters of antipsychotic drugs, thereby affecting their therapeutic efficacy and risk of adverse drug reactions. Available pharmacogenetic tests designed for identifying CYP2D6 phenotypes are also discussed with respect to their advantages and disadvantages in clinical use.